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                       Full Form 
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TC Total cholesterol 
LFT Liver function test 
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GDM Gestational diabetic melitus 
IFG Impaired fasting glucose 
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G6PD Glucose 6-phosphate dehydrogenase
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 INTRODUCTION 
Epidemiology 
Diabetes mellitus one of the most common and chronic disorder in 
world. But no one is not bothered about its severity & co-morbidity disorders. 
It increase the prevalence of diabetes is rapidly increasing in the world in a 
distressing rate, diabetes affect both developed and developing countries. 
Worldwide DM is currently estimated 368 million, 346 million in 2011& to 
affect 285 million (6.4%) adults aged 20–79 years and this number is 
projected to increase to 439 million (7.7%) adults by the year 2030 . Diabetes 
Atlas 2009 published by the International Diabetes Federation estimated 
diabetic population in India to around 50.8 million, which is expected to rise 
to 87 million by 2030, as per these calculation India will be a diabetes capital 
of the world. Type 2 diabetes (T2DM) accounts for approximately 85–95% of 
total reported cases of diabetes (Diabetes atlas). T2DM is a multifaceted 
disease involving lot of pathophysiological problems, it includes impaired islet 
function and insulin resistance, which results in impaired glucose tolerance 
and inappropriately increase fasting hepatic glucose production. Chances of 
developing T2DM are increased by obesity and physical inactivity and are 
further augmented with age. 
Definition 
Diabetes is a complex and a multivarious group of disorders that 
disturbs the metabolism of carbohydrates, protein and fat (Kahn CR& 
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Shechter 1991, Bliss M 2000) characterized by increased fasting (>110 
mg/dL) and postprandial blood sugar (>140mg/dL) levels.  
Classification of diabetes 
Diabetes mellitus is classified into two types- type I (insulin dependent 
diabetes mellitus, IDDM) and type II (non-insulin dependent diabetes mellitus, 
NIDDM). IDDM or juvenile onset diabetes is due to cell mediated 
autoimmune destruction of the β-cells of the pancreas (Aikinson MA& 
McLaren NK 1994, De-Fronzo 2009) However, NIDDM or adult-onset 
diabetes results from the development of insulin resistance and the affected 
individuals usually have insulin deficiency (Takeshi K, Shoichi N 2002  ) 
Patients suffering from type I are therefore totally dependent on external 
source of insulin but patients with Type II diabetes can be treated with dietary 
changes, exercise and medication 
             Two most important unmet needs for the management of T2DM are 
the lack of lasting efficacy in the reduction of increased glucose level and it 
fail to target primary causes. Poor glycemic control leads to increased 
morbidity, mortality and economics associated with T2DM (Turner RC et al., 
Ohkubo Y et al 1995., Koro CE et al., 2000) Though Lifestyle modification 
(Exercise, dietary management) provides the basis for metabolic control of 
patients with T2DM, but with diet modification is not enough to attain the 
normal blood sugar, need for introduction of anti-hyperglycemic agents. 
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Type 1 diabetes 
  Insulin-dependent diabetes, juvenile diabetes, Type 1 diabetes is 
characterized by cellular-mediated autoimmune destruction of islet ß-cells. 
Markers: 
 Islet cell antibodies (ICAs) 
 Auto-antibodies to insulin (IAAs) 
 Auto-antibodies to Glutamic Acid Decarboxylase (GAD65) 
 Auto-Antibodies to Tyrosine phosphatases IA-2 and IA-2ß 
Laboratory findings: 
 Hyperglycemia 
 Ketonuria (presence of ketone bodies in urine ) 
  Serum insulin & C-peptide levels 
 Auto-antibodies  
Type 2 diabetes 
  Type 2 diabetes is due to insulin insensitivity along with a failure of 
insulin secretion to overcome this by hyper secretion, resulting in relative 
insulin deficiency.  Type 2 diabetes is more common in individuals with 
family history of the disease, in individuals with hypertension.  
The risks of Type 2 diabetes are: 
 Family history of diabetes  
 Obesity  
 Age ≥ 45 years 
Chapter 1   Introduction 
 
Department of Pharmacy Practice J.K.K.M.M.R.F College of Pharmacy 
 
4
 Previously identified IFG or IGT 
 Hypertension  
 Reduced physical activity 
 History of gestational diabetes mellitus (GDM) or delivery of babies 
>4, 5 kg 
Sign & Symptoms of diabetes mellitus 
Symptoms may develop quite rapidly (weeks or months) in type 1 diabetes, 
particularly in children.  
¾ Fatigue 
¾ Increased thirst 
¾ Increased urination 
¾ Nausea 
¾ Vomiting 
¾ Weight loss    
¾ Diabetic ketoacidosis  
¾ Kussmaul breathing 
¾ Abdominal pain  
However, in type 2 diabetes symptoms usually develop much more slowly. 
¾ Increased fatigue  
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¾ Polydipsia  
¾ Polyuria  
¾ Polyphagia  
¾ Poor wound healing  
¾ Blurry vision  
¾ Irritability  
¾ Infections  
 
¾ Weight fluctuation  
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Diagnosis of diabetes 
The diagnosis of diabetes mellitus requires the identification of a 
glycemic cut point, which discriminates normal’s from diabetic patients, the 
present cut points reflect the level of glucose above which microvascular 
complications have been shown to increase.  
 
Criteria for the Diagnosis of Diabetes Mellitus 
Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L) 
                                                        or 
2-hour post load glucose ≥200 mg/dL (11.1 mmol/L)  
 
Diagnosis of diabetes is based on: 
• Typical symptoms of DM (Polyuria, Polydipsia, and weight loss). 
• Fasting plasma glucose > 126 mg/dL (7 mmol/L). 
•  2-h post load plasma glucose > 200 mg/dL (11.1 mmol/L)  
• Casual (random) plasma glucose > 200 mg/dL (11.1 mmol/L). (ADA 
1995) 
 
The pathophysiology of T2DM 
  T2DM as a progressive, complex metabolic disorder characterized by 
coexisting defects of multiple organ sites it includes insulin resistance in 
adipose tissue & muscle, is a progressive decline in pancreatic insulin 
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production, unrestrained hepatic glucose production, and other hormonal 
deficiencies, other defects include accelerated gastric emptying in patients 
with T2DM, especially those who are obese or long duration of diabetic 
history (Bertin E et al., 2001, Weytjens C et al., 1998). 
Hormonal deficiencies in T2DM are due to abnormalities in the 
production of hormones by beta-cell & its hormone amylin, the alpha-cell 
hormone glucagon, and the incretin hormones Glucagon-like peptide 1/8 
(GLP-1) & glucose-dependent insulinotropic polypeptide (GIP). (Fonseca et 
al., 2007) In addition to the triumvirate of core defects associated with T2DM 
(involvement of the pancreatic beta cell, muscle, and liver), other mechanisms 
of disease onset have been advanced, including accelerated lipolysis, 
hyperglucagonemia, and incretin deficiency/resistance also, the rate of basal 
hepatic glucose production is markedly increased in patients with T2DM, 
which is closely correlated with elevations in fasting plasma glucagon 
concentration (DeFronzo et al., 1997). 
The incretin effect the intestinal augmentation of secretion of insulin 
attributed to GLP-1 and GIP is reduced in patients with T2DM  
The secretion of GIP may be normal or elevated in patients with 
T2DM while the secretion of GLP-1 is deficient; however, cellular 
responsiveness to GLP-1 is preserved while responsiveness to GIP is 
diminished. (Heimesaat MM et al., 1994) Both endogenous and exogenous 
GLP-1 and GIP are degraded in vivo and in vitro by the enzyme DPP-4. The 
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role of DPP-4 in the immune system stems from its exo-peptidase activity and 
its interactions with various molecules, including cytokines and chemokines  
               Different classes of Oral Hypoglycemic Agents (OHA’s) are now 
available that target the different pathophysiologic factors contributing to 
T2DM: acarbose containing group delays carbohydrate absorption from 
intestine, metformin group (biguanides) are mainly target hepatic insulin 
resistance, pioglitazone group (thiazolidinediones) (TZDs) are targeting 
adipocyte and muscle insulin resistance and insulin secretagogues or 
sulfonylureas (SU) are targeted to improved insulin secretion by pancreatic 
beta cells (Cheng AY et al., 2005) . All the above mentioned classes have 
nearly equipotent efficacy; however, almost all of them are showing their own 
kind of adverse events. (Inzucchi SE et al., 2002).  The SU therapy shows two 
major adverse effects like weight gain and hypoglycemia (decreased blood 
sugar below normal). In the total diabetic patients  80% to 90% of people with 
diabetes are obese and SUs  worsen this condition (increased weight gain), it 
ranges from 2 to 5 kg and SU cause hypoglycemia affects the elder peoples 
those with irregular meal schedules ( Zimmerman et al., 1997, Schade et 
al.,1998, Kilo et al.,1992) 
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               Among the new type of oral anti diabetic therapies the DPP-4 
inhibitor vildagliptin shows very efficacious drug in reducing blood sugar in a 
wide range of T2DM patients, ranging from the impaired glucose tolerance 
(IGT) population to patients with advanced disease on insulin. Vildagliptin is 
consider as a second-line treatment option as a part of an oral combination 
therapy regimen in T2DM patients those increasing blood sugar is poorly 
controlled by monotherapy with metformin, a SU or a TZDs. Existing data 
indicates that HbA1c lowering potential of Vildagliptin also in range of TZDs 
and acarbose, with sustained reductions to clinically significant levels for up to 
2 years. When used as monotherapy or in combination with metformin or 
insulin, it shows modest reductions in HbA1c values have been showed in 
patients those using vildagliptin. 
Chapter 1   Introduction 
 
Department of Pharmacy Practice J.K.K.M.M.R.F College of Pharmacy 
 
10
T2DM is a disease due to the progressive decreasing of β-cell function. 
Unlike many other antihyperglycemic medications, oral inhibitor of DPP-4 
vildagliptin improves glycemic control in patients with T2DM through 
physiological mechanisms that result in an attenuation of β-cell decline and 
thus restoration of the incretin effect (Nauck et al., 1986, Drucker et al., 2003, 
Ahrén B 1994, Ahren B 2006). 
Complication 
All forms of diabetes increase the risk of long-term complications. 
These typically develop after many years (10–20), but may be the first 
symptom in those who have otherwise not received a diagnosis before that 
time. The major long-term complications relate to damage to blood vessels. 
Diabetes doubles the risk of cardiovascular disease. 
Themain"macrovascular"diseases (relatedto atherosclerosis of larger arteries) 
are ischemic heart disease  (angina and myocardial infarction), 
 stroke and peripheral vascular   disease. 
Diabetes also causes "microvascular" complications damage to the 
small blood vessels. Diabetic retinopathy, which affects blood vessel 
formation in the retina of the eye, can lead to visual symptoms, reduced vision, 
and potentially blindness. Diabetic nephropathy, the impact of diabetes on the 
kidneys, can lead to scarring changes in the kidney tissue, loss of small or 
progressively larger amounts of protein in the urine, and eventually chronic 
kidney disease  requiring dialysis. Diabetic neuropathy is the impact  
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of diabetes on the nervous system, most commonly causing numbness, 
tingling and pain in the feet and also increasing the risk of skin damage due to 
altered sensation. Together with vascular disease in the legs, neuropathy 
contributes to the risk of diabetes-related foot problems (such as diabetic foot 
ulcers) that can be difficult to treat and occasionally require amputation. 
 Vildagliptin 
The DPP-4 inhibitor vildagliptin is potent, selective and orally active 
2nd generation inhibitor of DPP-4, with a reversible and competitive 
mechanism of action. Vildagliptin binds and forms a complex with DPP-4, 
causing the inhibition of Dipeptidyl peptidase-4 (Brandt et al., 2005). This 
cause in improved glycemic control as calculated by Glycosylated 
haemoglobin (HbA1c) and fasting plasma glucose (FPG) levels. Vildagliptin 
presents several advantages over other anti-diabetic medications. Vildagliptin 
enhances α-cell responsiveness by suppressive action on hyperglycemia & 
stimulatory action on hypoglycemia.These effects contribute to the efficacy of 
vildagliptin to improve glycemic control as well as to its low hypoglycemic 
potential (Schweizer A et al., 2009). The effect of improving postprandial 
blood sugar provides a good alternative treatment option than that of former 
available drug therapies.  
Vildagliptin have generally well acceptance as monotherapy & in 
combination with other oral hypoglycemic agents. Especially combination of 
vildagliptin+ metformin shows highly beneficial lowering effects on 
Glycosylated haemoglobin, fasting blood sugar, random blood sugar. The 
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major role of an anti diabetic is to reduce the blood sugar only. But in some 
cases vildagliptin shows some subsidiary effects on lipid profile lowering like 
low density lipoprotein (LDL), very low density lipoprotein (VLDL), useful 
high density lipoprotein (HDL) increasing effect, and total cholesterol (TC) 
lowering, it’s side effect reporting also very low to compare with other anti 
diabetic drugs available in market. 
  
 
           Vildagliptin have unique mechanism of action allows a lot of 
combination regimens for effective control of glucose levels. Combining drug 
with other drugs with complementary mechanism of action makes us to 
provide a better therapeutic option for T2DM. Vildagliptin is highly beneficial 
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in combination with metformin or thiazolidinediones, with most important 
combination of drug being with metformin, because of it’s pathogenic point of 
view combination with metformin principally targeting insulin resistance with 
vildagliptin primarily targeting the β-cell is a rational approach. In add-on 
therapy to metformin, vildagliptin shows better blood sugar control than other 
drugs available in market(Rosenstock et al., 2007)and in an active comparator 
non inferiority trial, it was shown to be as effective as pioglitazone (Garber AJ 
et al.,2007). Also in other combination trials, vildagliptin as add-on therapy to 
insulin (Bosi et al., 2007), glimepiride (Fonseca et al., 2008) and pioglitazone 
(Schweizer et al., 2007) provided more effective glycemic control. 
                  DPP4 inhibitor (vildagliptin) was commonly well tolerated as 
monotherapy & combination therapy with other oral hypoglycemic agents. 
Adverse events shows by vildagliptin are generally of mild or moderate in 
nature, not that much Sevier and will be vanished in near future. The chance of 
occurrence of hypoglycemia due to vildagliptin treatment were least and when 
add on therapy to other oral hypoglycemic agents like metformin, pioglitazone 
or glibenclamide , the chances for the occurrence of hypoglycemia was not 
aggravated. And vildagliptin shows a weight-neutral and does not aggravate 
this problem as many of the antihyperglycemic agents. 
               The vildagliptin daily dose recommend as 100mg, and it 
administered as once daily or taken as two divided dose of 50mg in morning 
and night. When used in dual combination with sulfonylurea, the recommend 
dose of vildagliptin is 50mg once daily administered in the morning. Drug can 
be administered with or without meals. The preliminary evidence of beneficial 
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effects of Vildagliptin, member of the novel class of DPP-4 inhibitors, 
presents it to be an effective and safe antihyperglycemic agent. It has the 
potential to significantly change the clinical management of diabetes and can 
be an effective strategy to prevent or delay progression from the prediabetic 
state to over T2DM. 
Type-2 diabetic melitus is shows some sort of increased risk of organ 
complications like cardio vascular disease, hepatitis-C infection and 
pancreatitis & these complications could be aggravated by drug treatment. 
Subsequently alongside efficacy, safety profile of any new OHA is very 
important for the treatment of some chronic and progressive disease like     
type-2 diabetic melitus. Vildagliptin tolerability profile was reviewed 
previously. The major reported adverse drug reaction are of mild to moderate 
severity and transient in nature (Bolli G et al., 2008, Scherbaum et al.,2008, 
Schweizer A et al.,2009) with rare treatment related discontinuations. 
Side effect- tremor, headache, dizziness, low blood sugar, nausea and 
weakness. Patients taking vildagliptin may also experience weight gain and 
swelling the ankles of legs, this is because of increased fluid retention. Fatigue 
and constipation  
Precaution- should care on patients with type 1 diabetes or the patient under 
treatment for ketoacidosis. Caution in patient under haemodialysis. It is very 
harmful in patients with liver disorders, those patients with pre-treatment ALT 
or AST > 3x ULN. Liver function should be monitored during treatment with 
vildagliptin at three-month intervals during the first year and periodically 
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thereafter. Patients who develop jaundice or other signs suggestive of liver 
dysfunction should discontinue it. Following withdrawal of treatment with 
vildagliptin and LFT normalisation, treatment with vildagliptin should not be 
reinitiated. Monitoring for skin disorders, such as blistering or ulceration, is 
recommended while keeping with routine care of the diabetic patient. 
Drug interaction- Increased risk of hypoglycemia when used with other anti-
diabetic agents thus dose adjustments may be required. 
Contraindication- Hypersensitivity, Renal Disease ( serum creatinine levels 
≥1.5 mg/dL (>135 micromol/L) in males and ≥1.4 mg/dL (>110 micromol/L) 
in females or abnormal creatinine clearance, which may also result from 
conditions eg, cardiovascular collapse (shock), acute myocardial infarction 
and septicemia , Congestive Heart Failure, Diabetic Ketoacidosis 
Advantage- DPP-4 inhibitors appear to be extraordinarily well tolerated. 
Unlike traditional secretagogues (sulphonylureas and glinides), they seem 
unable to induce hypoglycemia, even at the highest doses. 
Disadvantage- Comparing the to other gliptins, vildagliptin has 
the disadvantage of being a twice daily medicine and being contraindication in 
hepatic impairment  (including patients with pre-treatment Alanine 
aminotransferase (ALT) or Aspartate aminotransferase (AST)> 3x the upper 
limit of normal) with the small benefit of a combination product. 
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Pioglitazone 
              Pioglitazone hydrochloride, a thiazolidinediones compound, is a new 
therapeutic agent for the treatment of type2 diabetes that reduces insulin 
resistance by enhancing insulin action in skeletal muscle, liver, and adipose 
tissue. (Whitcomb RW et al., 1971)The mechanism of action of the 
thiazolidinediones class has yet to be fully elucidated although mechanistic 
studies indicate that thiazolidinediones influence several process es to increase 
cell sensitivity to insulin (Saltiel AR et al., 1996, Grossman SL et al.,1997), 
including activation of peroxisome proliferator–activated receptor and 
alteration Of  hepatic glucose metabolism (Ciraldi TP et al.,1995, Spiegelman 
1998). 
               Pioglitazone having ability to reduce abnormal blood glucose level, 
increased insulin, and hypertriglyceridemia & it is characterized by insulin 
resistance (Sugiyama Y et al., 1990, Kemnitz JW et al., 1994). Pioglitazone 
shows metabolic changes by improving insulin response to tissues & it is 
observed in lot of models insulin resistance. Pioglitazone reduces insulin 
resistance by enhancing the action of insulin, thereby promoting glucose 
utilization in peripheral tissues, suppressing gluconeogenesis, and reducing 
lipolysis (Matthaei S et al.,2000,  Miyazaki Y et al., 2002). 
Side effects-feeling short of breath, even with mild exertion, swelling or rapid 
weight gain, chest pain,  general ill feeling nausea, stomach pain, low fever, 
loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the 
skin ) 
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Precaution- medical history, especially of: heart disease (such as congestive 
heart failure, chest pain), diabetic ketoacidosis, liver disease, fluid in your 
lungs, swelling (edema), anemia, a certain eye problem (macular edema). May 
experience blurred vision, dizziness, or drowsiness due to extremely low or 
high blood sugar levels. Do not drive, use machinery, or do any activity that 
requires alertness or clear vision until you are sure you can perform properly. 
Drug interaction -two drugs known to have a major interaction with 
pioglitazone. They are leflunomide, gatifloxacin 
Contraindication- Pioglitazone cannot be used in patients with a known 
hypersensitivity to pioglitazone, other thiazolidinediones or any of 
components of its pharmaceutical forms. It is ineffective and possibly harmful 
in diabetes mellitus type 1  and diabetic ketoacidosis acute diseases of the liver 
are regarded as a contraindication for pioglitazone. Pioglitazone and all other 
drugs of its class (Thiazolidinediones) are absolutely contraindicated in 
patients with heart failure. 
Advantage- the Proactive study provided some data suggesting that people 
who used pioglitazone to optimize their treatment may have an advantage in 
terms of deaths, non-fatal heart attacks and strokes. Pioglitazone shows fewer 
incidences of cardiac disorders while comparing to rosiglitazone. 
Disadvantage- It worsens the diabetic ketoacidosis &cardiac related 
problems.  
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Glibenclamide 
Is a second generation Sulfonylurea, Sulfonylurea are a class of oral 
hypoglycemic agent that has been used for the treatment of type 2 diabetes for 
more than 50 years. They are described as insulin secretagogues and act on a 
set of receptors on the β-cell, thereby increasing insulin secretion. Currently, 
three agents are mostly available they are glibenclamide, glipizide, and 
glimepiride. The three drugs are fairly similar in action. There is some 
evidence that glipizide and glimepiride may be associated with less 
hypoglycemia than glibenclamide. Unlike the action of other classes of 
available insulin secretagogues, which are glucose dependent, sulfonlyureas 
are not. The sustained effect on the β -cell contributes both to the degree of 
efficacy and also to the rate of hypoglycemia seen with this class.  Three drugs 
shows weight gain, in both cases as of mono & combination therapy with 
other classes of oral anti diabetic drug & with insulin (Hermann LS et al., 
1994, Lins PE et al., 1988, Kahn SE et al., 2006). In patients of glibenclamide 
gained 5.7 lb more than patients on nutrition therapy over a 10-year period. 
Increased and sustained insulin secretion, along with decreased glycosuria and 
increased hypoglycemia, are thought to fuel the weight gain seen with why 
this drug class. Sulfonylureas are not believed to have independent effects on 
adipose deposition or appetite. 
Side effects- nausea, stomach pain, low fever, loss of appetite, presence of 
dark coloured urine, clay color stools, jaundice (yellowing of the skin or 
eyes),pale coloured skin, confusion & weakness, easy bruising with or without 
bleeding, purple or red pinpoint  colored spots persistent sore throat or fever, 
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easy bleeding or bruising, stomach pain, yellow coloring of eyes & skin, dark 
urine, unusual tiredness or weakness, unusual or sudden weight gain, mood 
changes, hands or feet swelling , seizures. 
Precaution- sulfonylurea may have ability to produce uncontrolled lowering 
of blood sugar below normal, so selection of patient & dosage and instructions 
are important to avoid hypoglycemic episodes. Hepatic or renal insufficiency 
leads to increased drug levels distribution of glyburide and the latter may also 
totally decrease gluconeogenic capacity of the body, both of which cause the 
increased risk of serious hypoglycemic reactions. Elderly, debilitated or 
malnourished patients, and those with insufficiency of adrenal or pituitary 
glands , they have high chance to the hypoglycemic action of glucose-
lowering drugs. Hypoglycemic condition may can’t recognize properly 
especially in the elderly and in people under consumption of beta-adrenergic 
blocking regimens. Hypoglycemia is more likely to occur due to improper 
caloric consumption, after long time exercise, alcohol ingestion, or when 
under consumption of more than one glucose lowering drug. The risk of 
hypoglycemia may be increased with combination therapy. Loss of Control of 
Blood glucose when a patient stabilized on any diabetic regimen is exposed 
to stress such as fever, trauma, surgery, may cause loss of control. At that 
times necessary to with draw glibenclamide (glyburide) and injection of 
insulin. 
Drug interaction-hypoglycemia due to sulfonylureas may be increased by 
some other medication like non-steroidal anti-inflammatory drugs, and others 
like  highly protein bound salicylates, chloramphenicol, sulfonamides, 
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probenecid, coumarins, MAO inhibitors, and beta adrenergic blocking agents. 
When such drugs are administered to a patient receiving glibenclamide 
(glyburide), the patient should be observed closely for hypoglycemia. If the 
patient is under consumption of such drugs are withdrawn from a patient 
receiving glibenclamide. Some drugs produce hyperglycemia and may lead to 
loss of control, such drugs like corticosteroids, thiazides and other diuretics, 
phenothiazines,  estrogens, oral contraceptives, phenytoin, nicotinic acid, 
thyroid products,  sympathomimetics, calcium channel blockers, and 
isoniazid(INH). When such drugs are administered to a patient receiving 
glibenclamide (glyburide), if anybody taking should be closely observed for 
loss of control. If the withdrawal of such drugs leads patient receiving 
glibenclamide (glyburide) cause glucose lowering effect (hypoglycemia). 
There have a chance to interaction between glibenclamide to 
ciprofloxacin & oral miconazole ,  
Contraindication- hypersensitivity & allergy, diabetic ketoacidosis, with or 
without coma, in such condition can overcome by insulin.  
 Advantages- it has a beneficiary action on cardiac action potential shape. It is 
highly economical as compared to vildagliptin.  
Disadvantages- high chances of hypoglycemia, cardiac disfunctioning, 
chances of haemolytic anaemia 
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Acarbose 
  Acarbose is one of the anti-diabetic drug used to treat type 2 diabetes 
mellitus and, in some countries used for prediabetes condition also, Alpha-
glucosidase inhibitors (AGIs;acarbose, miglitol, voglibose) are widely  used in 
the treatment of patients with type 2 diabetes but not more prefer in single 
therapy.  Alpha-glucosidase inhibitors delay the absorption of carbohydrates 
from the small intestine and thus have a lowering effect on postprandial blood 
glucose and insulin levels. 
            Acarbose inhibits enzymes (glycoside hydrolases) needed to digest 
carbohydrates, to be specific, alpha-glucosidase are a type of enzymes present 
in the small intestinal brush border and pancreatic alpha-amylase. The enzyme 
pancreatic alpha-amylase will hydrolyzes complex starches 
to oligosaccharides at the small intestinal lumen, in this  membrane-bound 
intestinal alpha-glucosidase enzyme will hydrolyze oligosaccharides , 
trisaccharides, and disaccharides to glucose & other monosaccharides in the 
small intestine. The inhibition of these enzymes will reduce the rate of 
digestion of complex carbohydrates to simple one. So less glucose is absorbed, 
due to carbohydrates are not broken down into small glucose molecules. So 
the short-term effect of these drugs is to decrease current blood glucose levels; 
the long-term effect will cause the reduction in HbA1c level (Rutten et al.,). 
This reduction leads to absolute decrease of HbA1c values in diabetic patients. 
Side effect-  nausea , stomach pain, loss of appetite, dark urine, clay-colored 
stools. 
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Jaundice (yellowing of the skin or eyes).Less serious side effects may include 
mild stomach pain, gas, bloating, diarrhea, low fever 
          
Precaution-This medication should not be used if you have certain medical 
conditions. Before using this medicine, consult your doctor or pharmacist if 
you have: very high blood sugar levels (diabetic ketoacidosis), severe liver 
disease (cirrhosis), and intestine/bowel problems (e.g., inflammatory bowel 
disease, intestinal blockage/ulcers, and digestion/absorption disorders). 
Drug interaction- certain drugs tend to produce hyperglycemia and may lead 
to loss of glucose control. It includes corticosteroids, thiazide & other 
diuretics, estrogens, oral contraceptives, thyroid products, phenytoin, nicotinic 
acid, sympathomimetics, calcium channel-blockers, and INH. If the patient 
under consumption with such drugs is administered to a patient receiving 
acarbose, should be closely observed because there is a chance of loss of blood 
glucose control, when ever withdrawn such drugs then recommend the patient 
to take acarbose in combination with sulfonylureas or insulin & patients 
should be observed closely for hypoglycemia. 
Patients under consumption of insulin may leads to hypoglycemic 
condition. Acarbose as combination with sulfonylurea or insulin may also 
leads to further lowering of blood glucose. If hypoglycemia occurs, 
appropriate adjustments in the dosage of these agents should be done. Very 
rare chances of  hypoglycemic shock have been reported in patients receiving 
acarbose therapy in combination with sulfonylureas and/or insulin. 
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Intestinal adsorbents like charcoal and digestive enzyme  preparations 
containing carbohydrate-splitting enzymes like amylase, and pancreatin may 
decrease the effect of acarbose, so avoid concomitant consumption of both. 
Acarbose have ability to change the bioavailability of digoxin when it 
co-administered, in this may require digoxin dose adjustment. 
Contraindication-it is contraindicated in patients with hypersensitivity 
reaction, & it is contraindicated in patients with diabetic 
ketoacidosis & cirrhosis. And also contra- indicated in patients with IBD 
(inflammatory bowel disease), partial intestinal obstruction, colonic ulceration, 
or in patients predisposed to  intestinal obstruction. And patients who have 
chronic intestinal diseases associated with digestion or absorption.  
Combination therapy 
 The major combination therapy of vildagliptin is with metformin& 
pioglitazone are widely preferred now a days, its combined action is more 
beneficiary as well as less side effect comparatively with their individual 
therapy. Combined action of vildagliptin with metformin produce improved 
glycemic control .Vildagliptin works by increasing the amount of two body 
incretin hormones, like glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP), these hormones are normally 
produced naturally by the body with respect to food consumption. The 
hormone’s function is to control(maintain as normal )blood sugar level. 
Primarily, they stimulate the pancreas to produce insulin in response to 
increasing levels of glucose in the blood and metformin improves 
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hyperglycemia primarily by suppressing glucose production by the liver 
(hepatic gluconeogenesis). Metformin activates AMP-activated protein kinase 
(AMPK), an enzyme that plays an important role in insulin signaling, whole 
body energy balance, and the metabolism of glucose and fats; activation of 
AMPK is required for metformin’s inhibitory effect on the production of 
glucose by liver cells. In the combination therapy of vildagliptin with 
pioglitazone was improved incretin hormones production as well as increased 
cell sensitivity to insulin, including activation of peroxisome proliferators 
activated receptor and alteration of hepatic glucose metabolism, and promote 
glucose utilization in peripheral tissues. 
Side effects-its side effects may vary with individual people in different ways. 
The major known side effects associated with this medicine are  
• Headache (when used with metformin or a sulphonylurea). 
• Dizziness (with metformin or a sulphonylurea). 
• Low blood sugar levels (with metformin or a sulphonylurea). 
• Nausea (with metformin). 
• Feeling weak (with a sulphonylurea). 
• Weight gain (with a glitazone). 
• Swelling of the legs and ankles due to excess fluid retention (with a 
glitazone). 
• Tremor (when used with metformin or a sulphonylurea). 
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Precaution-never use with patients having type 1 diabetes ,diabetic 
ketoacidosis, Do not use in patients having hepatic impairment, including 
patients have pre-treatment ALT or AST > 3x ULN. Liver function should be 
monitored during treatment with vildagliptin at three-month intervals during 
the first year and periodically thereafter. Patients who develop jaundice or 
other signs suggestive of liver dysfunction should discontinue it. 
Advantage- DPP-4 inhibitors appear to be extraordinarily well tolerated with 
metformin & Pioglitazone. 
 Disadvantages- it is not economical compare to other oral anti hypoglycemic 
agent. 
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LITERATURE REVIEW 
Stephen aronoff et al., 2000, conducted a study of pioglitazone monotherapy 
treatment in type 2 diabetes; the objective of the study is to evaluate the efficacy and 
safety of four doses of pioglitazone monotherapy in the treatment of patients with 
type 2 diabetes. There were 408 patients randomized in this multicenter double-blind 
placebo-controlled clinical trial. Patients who had HbA1c_7.0%, fasting plasma 
glucose (FPG) 140 mg/dl, and C-peptide 1 ng/ml were randomized to receive placebo 
or 7.5, 15, 30, or 45 mg pioglitazone administered once a day for 26 weeks. Patients 
treated with 15, 30, or 45 mg pioglitazone had significant mean decreases in HbA1c 
and FPG. In the 15, 30, or 45-mg pioglitazone groups, there were significant mean 
percent decreases in triglycerides, significant mean percent increases in HDL 
cholesterol,and only small percent changes in total cholesterol and LDL. The subset 
of patients naive to therapy had greater improvements in HbA1c and FPG compared 
with previously treated patients. The overall adverse event profile of pioglitazone was 
similar to that of placebo. 
 
Phillips et al., 2003, conducted the study of glycemic control of Acarbose in over 
weight patient having type 2 Diabetes, objective of the study to investigate the 
efficacy and safety of acarbose as add-on therapy in overweight type 2 patients with 
diabetes inadequately controlled by metformin. And it conducted a multicenter, 
randomized, double-blind, placebo-controlled, parallel group design. After a 4-week 
placebo run-in period, subjects were randomized to either acarbose (titrated up to 100 
mg b.i.d.) or placebo. The primary efficacy variable was the change in HbA1c from 
baseline to the end of the 24-week treatment period. Change in fasting blood glucose 
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was assessed as a secondary efficacy parameter. And they concluded the analysis 
from baseline to week 24 (81 patients for HbA1c and 82 for fasting blood glucose) 
showed statistically significant differences between acarbose and placebo treatment in 
HbA1c and fasting blood glucose. 18 patients (47%) in the acarbose group were 
classified as responders with a 5% reduction in HbA1c (relative to baseline) at the end 
point compared to 6 (14%) in the placebo group. The safety profiles were similar for 
both treatment groups except for the higher incidence of gastrointestinal side effects 
during acarbose therapy. 
 
Schernthaner et al., 2004, conducted a study on efficacy and safety of Pioglitazone 
Vs Metformin in patients with Type 2 Diabetes mellitus. This study compared 
metabolic control in drug-naive type 2 diabetes patients given either pioglitazone or 
metformin. Eleven hundred and ninety-nine patients with poorly controlled type 2 
diabetes mellitus (HbA1c), 7.5–11%; were randomized to receive either pioglitazone 
(<45 mg/d) or metformin (<850 mg, three times daily). HbA1c, fasting plasma 
glucose (FPG), insulin levels, total cholesterol (TC), high density lipoprotein 
cholesterol (HDL-C), low density lipoprotein cholesterol, triglycerides, free fatty 
acids, and urinary albumin/creatinine ratio were measured. The assessed result were 
Mean HbA1c decreased in both treatment groups from baseline to wk 52 (1.4% 
and1.5%). Significantly greater mean reductions in FPG were observed in the 
pioglitazone group than in the metformin  group (P_ 0.016). Favourable changes in 
triglycerides and HDL-C were more pronounced with pioglitazone. 
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Smith et al., 2004, conducted a study on Rosiglitazone, But Not Glyburide, Reduces 
Circulating Proinsulin and the Proinsulin: Insulin Ratio in Type2 Diabetes. Objective 
of the studies was to assess the effects of the thiazolidinedione insulin sensitizer, 
rosiglitazone, on indirect markers of cell function and cardiovascular risk in people 
with type 2 diabetes by measuring plasma PI and the PI : IRI ratio. Type 2 diabetes 
patients enrolled in two randomized double-blind studies comparing the effects of 
rosiglitazone (4 or 8 mg/d) with placebo (study 1, 26-wk treatment)or the sulfonylurea 
glyburide (study 2, 52-wk treatment).Treatment with rosiglitazone for 26 wk (study 
1)produced significant dose-dependent decreases in both plasma PI concentrations 
(18–29%) and the PI:IRI ratio compared with baseline (7–14%) and placebo (19–
29%) (P < 0.001).A significant increase in the PI: IRI ratio in placebo-treated patients 
occurred (P < 0.001). In study 2, rosiglitazone also significantly reduced both plasma 
PI and the PI: IRI ratio compared with baseline (P < 0.001). In contrast, glyburide 
significantly increased both plasma PI (45%; P < 0.001) and the PI: IRI ratio (10%) 
(P < 0.05 vs. baseline). These results show that rosiglitazone and glyburide have 
differential effects on absolute PI levels and the PI: IRI ratio in people with type 2 
diabetes. 
 
C.Pan et al., 2007, conducted a comparative study of Vildagliptin Vs Acarbose 
monotherapy in type 2 diabetic patients, the aim of the study to compare the efficacy 
and tolerability of the dipeptidyl peptidase-4 inhibitor, vildagliptin, with the alpha 
glucosidase inhibitor, acarbose, in drug-naive patients with Type 2 diabetes. multi-
centre, randomized, double-blind, parallel-arm study compared the efficacy and 
tolerability of vildagliptin (100 mg daily, given as 50 mg twice daily,n= 441) and 
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acarbose (up to 300 mg daily, given as three equally divided doses,n= 220) during 24-
week treatment. The assessed result where Monotherapy with vildagliptin or acarbose 
decreased HbA1c to a similar extent during 24-week treatment. The  
decrease in fasting plasma glucose was similar with acarbose and vildagliptin .Body 
weight did not change in vildagliptin-treated patients but decreased in acarbose-
treated patient.The proportion of patients experiencing any adverse event (AE) was 
35% vs. 51% in patients receiving vildagliptin or acarbose, respectively; 
gastrointestinal AEs were significantly more frequent with acarbose (25.5%) than 
vildagliptin (12.3%). No hypoglycaemia was reported for either group. 
 
 Julio rosenstock et al., 2008, conducted study on effects of the Dipeptidyl Peptidase-
IV Inhibitor Vildagliptin  on Incretin Hormones, Islet Function, and Postprandial 
Glycemia, the objective of the study to determine the effects of vildagliptin on 
incretin hormone levels, islet function, and postprandial glucose control in subjects 
with impaired glucose tolerance (IGT).2-week, double-blind, randomized, parallel-
group study comparing vildagliptin (50 mg q.d.) and placebo was conducted in 179 
subjects with IGT (2-h glucose 9.1 mmol/l, A1C 5.9%). Plasma levels of intact 
glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP), glucose, 
insulin, C-peptide, and glucagon were measured during standard meal tests performed 
at baseline and at week 12.study assessed by ANCOVA method vildagliptin increased 
GLP-1 and GIP and decreased glucagon. Although postprandial insulin levels were 
unaffected, prandial glucose excursions were reduced, representing an_30% decrease 
relative to placebo. 
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D’alessio et al., 2008, conducted study on Treatment with the Dipeptidyl Peptidase-4 
Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 
Diabetes; the objective of the study was to examine the effects of DPP-4 inhibition  
on fasting islet function. It’s a randomized, double-blind, placebo-controlled trial. 
Conducted on a Fourty-one subjects withT2DM were treated with metformin or diet, 
having good glycemic control with Glycosylated haemoglobin values of 6.2–7.5%. 
Subjects were treated with vildagliptin (50 mg twice daily) or placebo for 3 months, 
followed by a 2-wk washout .and  measured insulin secretion in response to iv 
glucose and arginine before and after treatment and after drug washout. small and 
comparable reductions in glycosylated haemoglobin in both groups over 3 months. 
Vildagliptin increased fasting GLP-1 levels in subjects taking metformin, but not 
those managed with diet, and raised active GIP levels slightly. DPP-4 inhibitor 
treatment improved the acute insulin and C-peptide responses to glucose (50 and 
100% respectively; P 0.05) and increased the slope of the C-peptide response to 
glucose (33%; P 0.023). DPP-4 inhibition has metabolic benefits in addition to 
enhancing meal-induced GLP-1 and GIP activity. 
 
Bo ahrén, 2008, Department of Clinical Sciences, Division of Medicine, Lund 
University, run a study on combination therapy of DPP4 inhibitor  Vildagliptin and 
Metformin in type 2 diabetic patients, clinical experience with DPP-4 inhibition is 
based on vildagliptin (GalvusR, Novartis) and sitagliptin (JanuviaR, Merck) where 
assessed during a 52 weeks combination versus continuous therapy with metformin 
alone . Both have also been shown to efficiently improve glycemic control when 
added to ongoing metformin therapy in patients with inadequate glycemic control. 
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They reduce HbA1c levels by 0.65%–1.1% (baseline HbA1c 7.2–8.7%). The 
combination of DPP-4 inhibition and metformin has been shown to be highly 
tolerable with very low risk of hypoglycemia. Hence, DPP-4 inhibition in 
combination with metformin is an efficient, safe and tolerable combination therapy 
for type 2 diabetes. 
 
Mikhai, 2008 conducted the study on combination therapy with DPP4 inhibitors and 
Pioglitazone in type 2 diabetis. The objective of this study is to critically evaluate 
sitagliptin and vildagliptin in combination with pioglitazone. The result was to be 
vildagliptin to ongoing pioglitazone therapy is associated with reduction in average 
hemoglobin A1C (HbA1c) levels of approximately 0.7% compared with placebo and 
1% compared with baseline after 24 weeks. When started concomitantly in drug-naïve 
patients, the combination of pioglitazone 30 mg and vildagliptin 100 mg qd reduces 
HbA1c by 1.9% after 24 weeks, compared with 1.1% with pioglitazone monotherapy. 
In general, the addition of DPP-4 inhibitors to pioglitazone was well tolerated, did not 
increase the incidence of hypoglycaemia, and did not substantially worsen the weight-
gain induced by pioglitazone. The combination of sitagliptin or vildagliptin with 
pioglitazone can be a useful therapeutic approach in patients with type 2 diabetes who 
cannot tolerate metformin or a sulfonylurea. 
 
Mathieu & Degrande, 2008, conducted study on vildagliptin: a new oral treatment 
for type 2diabetes mellitus. Vildagliptin involving approximately 22,000 patients and 
7000 patient-years of exposure to vildagliptin has shown that the agent is well 
tolerated and efficacious in improving glycemic control in patients with type 2 
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diabetes mellitus (T2DM). Monotherapy trials have shown that significant HbA1c 
lowering is accompanied by body weight-neutral and lipid-neutral effects, low risk of 
oedema, and low risk of hypoglycemia.These characteristics make vildagliptin a 
favourable partner for combination therapy. Studies of vildagliptin as an add-on to 
metformin have shown significant improvements in glycemic control (comparable to 
that of thiazolidinedione add-on), with the combination being well tolerated and 
associated with low risks for hypoglycemia and adverse effects on weight or lipid 
levels. 
 
Ahr´en et al., 2010, studied Changes in Prandial Glucagon Levels After a 2-Year 
Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes 
Inadequately Controlled With Metformin Monotherapy, objective of the study to 
determine if the dipeptidyl peptidase-4 inhibitor vildagliptin more effectively inhibits 
glucagon levels than the sulfonylurea glimepiride during a meal. Glucagon responses 
to a standard meal were measured at baseline and study end point (mean 1.8 years) in 
a trial evaluating add-on therapy to metformin with 50 mg vildagliptin b.i.d. 
compared with glimepiride up to 6 mg q.d. in type 2 diabetes (baseline A1C 7.3 ± 
0.6%). A1C and prandial glucose area under the curve (AUC) 0–2 h were reduced 
similarly in both groups, whereas prandial insulin AUC 0–2 h increased to a greater 
extent by glimepiride. Prandial glucagon AUC 0–2h decreased by vildagliptin (n 137) 
and increased by glimepiride (n 121). The between-group difference was 7.3 ± 2.1 
mol . Vildagliptin therapy but not glimepiride improves postprandial cell function, 
which persists for at least 2 years. 
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Schweizer et al., 2011, conducted a study to assess the general safety & tolerability of 
Vildagliptin in type 2 diabetic patients. The aim of this study is therefore to assess the 
general safety and tolerability, including incidences of the most common adverse 
events (AEs).The study conducted by 38 studies of ≥12 to ≥104 weeks’ duration. AE 
profiles of vildagliptin (50 mg bid; N = 6116) were evaluated relative to a pool of 
comparators (placebo and active comparators; N = 6210). Absolute incidence rates 
were calculated for all AEs, serious AEs (SAEs), Discontinuations due to AEs, and 
deaths. The results was to be Overall AEs, SAEs, discontinuations due to AEs, and 
deaths were all reported with a similar frequency in patients receiving vildagliptin 
(69.1%, 8.9%, 5.7%, and 0.4%, respectively)and patients receiving comparators 
(69.0%, 9.0%, 6.4%, and 0.4%, respectively), whereas drug related AEs were seen 
with a lower frequency in vildagliptin-treated patients (15.7% vs. 21.7% with 
comparators). The incidences of the most commonly reported specific AEs were also 
similar between vildagliptin and comparators, except for increased incidences of 
hypoglycaemia, tremor, and hyperhidrosis in the comparator group related to the use 
of sulfonylurea. 
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AIM AND OBJECTIVE 
 
Aim 
To compare the efficacy & safety of DPP4 inhibitor Vildagliptin with or without 
Biguanide derivative Metformin, Alfa glucosidase inhibitor acarbose, Sulfonylurea 
derivative  Glibenclamide, Thiazolidinedione derivative Pioglitazone & DPP4 
inhibitor Vildagliptin with Thiazolidinedione derivative Pioglitazone. 
 
Objective 
 
• Compare the efficacy & safety of DPP4 inhibitor Vildagliptin with or without 
Biguanide derivative Metformin to Alfa glucosidase inhibitor acarbose. 
 
• Compare the efficacy & safety of DPP4 inhibitor Vildagliptin with or without 
Biguanide derivative Metformin to Sulfonylurea derivative Glibenclamide. 
 
• Compare the efficacy & safety of DPP4 inhibitor Vildagliptin with or without 
Biguanide derivative Metformin to Thiazolidinedione derivative Pioglitazone. 
 
• Compare the efficacy & safety of DPP4 inhibitor Vildagliptin with or without 
Biguanide derivative Metformin to DPP4 inhibitor Vildagliptin with 
Thiazolidinedione derivative Pioglitazone. 
 
Chapter 4  Plan of work 
Department of Pharmacy Practice J.K.K.M.M.R.F College of Pharmacy 
 
35
                      PLAN OF WORK 
This is designed in three different phases to achieve the objectives.  
PHASE 1 
• Initial study to identify the scope of work. 
• Literature survey. 
• Preparation of study protocol. 
 
PHASE 2 
• Gaining consent from hospital authority. 
• Designing of data entry format. 
Based on the topic articles were collected. From the different articles 
prepare the interview questionnaire form with the help of standard 
references. Prepared questionnaire was discussed with guide. 
• Data collection. 
 
PHASE 3 
• Analysis of data 
 All data’s were coded, entered, and analyzed using Data analysis was done 
with the help of computer using  Epidemiological Information Package (EPI 
2010) developed by Centre for Disease Control, Atlanta.  
• Report and submission. 
Chapter 5  Methodology 
 
Department of Pharmacy Practice J.K.K.M.M.R.F College of Pharmacy 
 
36
MATERIALS AND METHODS 
 
Study design  
              This is a prospective observational study (one in which the data to be studied 
are yet to be generated, the events having not yet occurred.)  
Study site 
               This study was conducted in Dialife diabetic & obese centre Manjeri - 
Kerala, is a hundred bed hospital, specially designed for diabetic and associated 
diseases like diabetic neuropathy (foot ulcer) & retinopathy.  
Duration of study 
Present prospective study was carried out in between June 2011 to March 2012. 
Study population 
Total number of population is two hundred and eighty (280) from that two 
hundred and seven (207) patients are selected & seventy three patients had dropped 
due to irregular follow up. 
Study criteria 
Inclusion criteria 
 Age category-30 to 8o. 
 The patients who have HbA1c range in between 5 to 10. 
 Patients those are taking only oral anti diabetic agents. 
 The patients those have normal or near normal AST & ALT values. 
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Exclusion criteria 
 Patients those under insulin injection. 
 Patients with life threatening diseases like Angina pectoris, CAD etc. 
 Patients with foot ulcer. 
 Patient with gestational diabetis. 
 Patients with type 1 Diabetis. 
Sources of data 
 Direct observational & questionnaire method. 
 Lab report collection. 
 Patients prescription 
 Method of data collection 
 By this study demographical data’s were collected by using 
questionnaire form with proper personal interview to the patients, 
in this demographical data’s included as follows age, sex, BMI, 
Educational Qualification, social history and Family history. Other 
data’s like symptoms, co-morbidity, drug category also included.   
 On the first visit onwards we starting the procedure, as per the 
proforma collect all the data like demographic, lab data like 
efficacy & safety profile.  
 Collect blood sample for following tests FBS, RBS, HbA1c, lipid 
& hepatic safety profile by lab technician. The same procedures 
continue on 2nd& 3rd visit. But not conducting HbA1c test in 
second visit. 
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RESULT & DISCUSSION 
All together two hundred and seven (207) patients were enrolled in to the 
study over a period of 10 months from department of diabetes, dialife diabetic & 
obese centre Manjeri. 
DEMOGRAPHIC DATA:- 
Sex & Age wise Distribution (n=207):- 
Of the two hundred and seven (207) patients examined, In that males 133 
(64.25%) and   females 74 (35.74%). The total patients are classified in to two groups 
based on the number of drug consumption (Monotherapy & Combination therapy) in 
monotherapy group males 86(64.7%) & females 47(35.3%) are there out of 133,in 
combination therapy consist of 74 patients in that 47(63.3%) males & 27 
females(36.5%). The mono & combination therapy again sub divided in to six on the 
basis of drug prescribed. The sex wise distribution from each group more males 30 
(75 %) out of 40 is in vildagliptin + metformin group, more females 18 (38.6 %) out 
of 47 in glibenclamide group.   
In age wise distribution two hundred and seven (207) patients are divided in to 
five age groups. They are 35-45 year, 46-55 year, 56-65 years, 66-75 years, and 76-85 
years. In that more patients 67 (32.36%) are in age group of 46-55 years & 56-65 
years in each group. Study of  Muralikrishnan R et al., 2001 also shows the 
prevalence of diabetic in age group of 50 and above, The least number of patients 4 
(1.93%) are present in 76-85 year age group.  
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Table .1 Age & Sex wise distribution of patient 
 
   Parameters 
Monotherapy therapy Combination therapy 
vildagliptin Pioglitazone Glibenclamide Acarbose Vildagliptin+
Metformin 
Vildagliptin+ 
Pioglitazone 
Total 
patient
s 
207 
No 34 39 47 13 40 34 
% 16.42 18.84 22.72 6.28 19.32 16.42 
Male-133 
Female-74 
No % No % No % No % No % No % 
 
Sex  
Male 21 61.76 25 64.1 29 61.7 10 76.92 30 75 18 52.94 
Femal
e 
13 38.24 14 35.9 18 38.6 3 29.08 10 25 16 47.06 
 
 
 
Age 
 In 
years 
35-45 4 11.76 15 38.46 15 31.91 6 46.15 6 15 2 5.88 
46-55 15 44.12 12 30.77 19 40.43 Ni
l 
0 14 35 7 20.59 
56-65 14 41.18 10 25.64 11 23.4 4 30.77 14 35 14 41.18 
66-75 1 2.94 2 5.13 1 2.13 3 23.08 5 12.5 9 26.47 
76-85 Nil 0 Nil 0 1 2.13 Ni
l 
0 1 2.5 2 5.88 
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Figure.1a Sex wise distribution of patients 
 
 
Figure.1b Age wise distribution of patients 
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Family history & duration of therapy report (n=207):- 
              Among the study population 176 (85.02%) have family history of diabetes 
mellitus & 31(14.97%) doesn’t with family history. According to American Diabetes 
Association (ADA) Type 2 diabetes has a stronger link to family history and lineage 
than type 1, although it too depends on environmental factors. Studies of twins have 
shown that genetics play a very strong role in the development of type 2 diabetes. 
Lifestyle also influences the development of type 2 diabetes. In drug wise family 
history as follows, the patients with vildagliptin  30 (88.2%)have family history and 4 
(11.7%) doesn’t have family history, in pioglitazone group 32 (82%) have family 
history and 7 (17.9%) doesn’t have, in glibenclamide group 37(78.72%) have family 
history and 10(21.28%) doesn’t have, in acarbose group 10 (76.9%) have history and 
3(29%) doesn’t have, in vildagliptin+metformin combination group 37 (92.5%) have 
family history  3 (7.5%) doesn’t have family history, in vildagliptin+pioglitazone 
group 30(88.2%) have family history of diabetes mellitus and  4 (11.7%) haven’t 
family history of diabetes mellitus. The details of family history of diabetes mellitus 
patients are presented in Table 2 and Figure 2a. 
In the study population, 34 patients (16.42%) had a treatment history of less 
than 1 year, followed by 1-5 year in 71 patients (34.29%), followed by 5-10 years in 
70 patients (33.81%), followed by >10 years in 32 patients (15.45%), The details of 
duration of therapy type of  2 diabetes mellitus are presented in Table 2 and Figure 
2b. 
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Table 2 Duration of therapy & Family history report
                           
 
 
 
 
Parameters 
                                  
                                   Monotherapy 
 
    Combination therapy 
 
Vildagliptin 
 
Pioglitazone 
 
 
Glibenclamide
 
Acarbose 
 
Vildagliptin+ 
Metformin 
 
Vildagliptin+ 
Pioglitazone 
 
No 
 
 % 
 
N0 
 
  % 
 
No 
 
   % 
 
No
 
% 
 
No 
 
% 
 
No 
 
% 
 
 
 
Duration 
     of 
Therapy 
(in 
years) 
 
< 1 
 
Nil 
 
0 
 
14 
 
35.9 
 
14 
 
29.79 
 
4 
 
30.7
 
2 
 
5 
 
Nil 
 
0 
 
1-5 
 
2 
 
5.8 
 
21 
 
53.8 
 
28 
 
59.58 
 
7 
 
53.9
 
10 
 
25 
 
3 
 
8.82 
 
5-
10 
 
24 
 
70.5 
 
3 
 
7.7 
 
2 
 
4.26 
 
1 
 
7.69
 
18 
 
45 
 
22 
 
64.8 
 
>10 
 
8 
 
23.5 
 
1 
 
2.56 
 
3 
 
6.38 
 
1 
 
7.69
 
10 
 
25 
 
9 
 
26.5 
 
 
Family 
history 
 
 
Yes 
 
 
30 
 
 
88.2 
 
 
32 
 
 
82. 
 
 
37 
 
 
78.72 
 
 
10 
 
 
76.9
 
 
37 
 
 
92.5 
 
 
30 
 
 
88.2 
 
 
No 
 
 
4 
 
 
11.7 
 
 
7 
 
 
17.9 
 
 
10 
 
 
21.28 
 
 
3 
 
 
29.0
 
 
3 
 
 
7.5 
 
 
4 
 
 
11.7 
Chapter 6 Results 
 
Department of Pharmacy Practice J.K.K.M.M.R.F College of Pharmacy 
 
43
 
 
Figure.2a Diabetic related Family history of patient 
 
 
Figure.2b Duration of therapy 
Body Mass Index (BMI) result:-    
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Body mass index of two hundred and seven patients (207) was observed and 
marked in initial& final therapy period that data is mentioned in the Table-3& Figure 
3, in that we can assess the pre, post & their changes of the BMI in (mean ± SD).  
Table 3-Body mass index wise distribution of patients 
 
            
            Group 
 Body mass index(BMI)               
P value  
 
 
 Initial 
therapy 
Final 
therapy 
Change in 
BMI 
Mean ± SD Mean ± SD Mean ± SD 
Monotherapy 
Vildagliptin 
Glibenclamide 
Pioglitazone 
Acarbose 
 
 
25.49 ± 2.29 
25.24 ± 2.45 
25.74 ± 2.69 
26.81 ± 3.45 
 
 
24.73 ± 2.39 
25.4 ± 2.44 
25.96 ± 2.6 
27.06 ± 3.44 
 
 
0.24±0.52 
-0.16±0.43 
-0.22±0.43 
-0.25±0.39 
           
 
 
 
 
0.0001 
Significant 
Combination 
therapy 
Vildagliptin  + 
Pioglitazone 
Vildagliptin 
+Metformin 
 
25.32 ± 2.29 
 
27.43 ± 2.93 
 
25.56 ± 2.29 
 
27.02 ± 2.8 
 
-0.24±0.32 
 
0.41 ± 0.53 
 
In the monotherapy group the acarbose group patients pre treatment BMI 
(26.81 ± 3.45) & post treatment BMI (27.06 ± 3.44) are higher than that of other 
groups & also it showing higher negative weight decrease (weight gain) (-0.25 ± 
0.39). Study of Delgado H et.al, 2002 shows Variable effects on weight have been 
seen with acarbose, Vildagliptin group patients pretreatment BMI (25.49 ±2.29) is 
more than that of Glibenclamide (25.24 ± 2.45) group, but post treatment BMI of 
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vildagliptin (24.73 ±2.39) is  lesser than that of  Glibenclamide (25.4 ±2.44)  and also 
the vildagliptin group only shows positive weight (0.24 ± 0.52) decrease. Pioglitazone 
group also shows a negative weight decrease (-0.22±0.43) Richard e Pratley et al., 
study also shows the same effect of thiazolidinediones (pioglitazone). In combination 
therapy Vildagliptin + Metformin group (0.41 ± 0.53) showing greater decline of 
body weight than Vildagliptin+ Pioglitazone (-0.24 ± 0.32) group. 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Figure.3 Body mass index chart 
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Fasting blood sugar (FBS) level in diabetic patients:-  
Fasting blood sugar of two hundred and seven (207) patients was observed and 
marked in pre& post treatment period that data is mentioned in the Table-4& Figure 
4, in that we can assess the pre, post & their changes of the BMI in (mean ± SD).  
Table 4-Fasting blood sugar distribution in diabetic patients 
 
Group 
Fasting blood sugar(FBS)  
P value 
 
 
Pre 
treatment 
Post 
treatment 
Change in    
FBS 
Mean ± SD   Mean ± SD   Mean ± SD 
Monotherapy 
Vildagliptin 
Glibenclamide 
Pioglitazone 
Acarbose 
 
142.6 ± 36.0 
135.4 ± 33.2  
130.4 ± 36.3 
151.1 ± 34.5 
 
107.6 ± 23.7 
119.2 ± 43.4 
116.5 ± 28.3 
161.2 ± 39.1 
 
35.0 ± 22.8 
16.2 ± 31.7 
13.9 ± 24.4 
-10.1 ± 32.6 
 
 
   
  0.0001  
Significant 
Combination 
therapy 
Vildagliptin + 
Pioglitazone 
Vildagliptin + 
Metformin 
 
                        
139.1 ± 29.7 
  
161.1 ± 48.5 
 
                       
107.4 ± 33.4 
 
124.6 ± 31.8 
 
                       
31.8 ± 47.4 
 
36.5 ± 27.6 
 
In that monotherapy group vildagliptin pre-treatment mean value (142.6±36.0) 
is greater than that of other group but its post-treatment day value (107.6 ± 23.7) is 
lesser than that of the pre-treatment day value of other group live glibenclamide, 
pioglitazone & acarbose. And also it shows a high mean decrease range (35.0 ± 22.8) 
than other groups. Harvey et al., study shows the vildagliptin has better effect & 
increased incretin hormone than Pioglitazone.  Mathieu and Degrande Studies shows 
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a better decrease of fasting blood sugar without inducing hypoglycemia. The acarbose 
monotherapy post-treatment day mean value (161.2 ± 39.1) is more than that of pre-
treatment day mean value (151.1 ± 34.5), that means it shows a less control or 
negative decrease of fasting blood sugar (-10.1 ± 32.6) level. In combination therapy 
group vildagliptin+metformin combination showing a pre &post treatment day FBS 
values of 161.1 ± 48.5, 116.6 ± 33.5, that means it shows a better mean FBS reduction 
(36.5 ± 27.6) than that of vildagliptin+pioglitazone group (31.8 ± 47.4).In both (mono 
& combination) group comparison also vildagliptin+metformin combination (36.5 ± 
27.6) shows better decrease than that of vildagliptin alone & vildagliptin+pioglitazone 
combination. And shows a significant P (0.0001) value decrease. 
 
 
 
 
 
 
 
 
 
 
 
             
   Figure. 4 Fasting blood sugar level 
 
Chapter 6 Results 
 
Department of Pharmacy Practice J.K.K.M.M.R.F College of Pharmacy 
 
48
Random blood sugar (RBS) level data:- 
Random blood sugar of two hundred and seven (207) was observed and marked 
in pre& post therapy period that data is mentioned in the Table-5 & Figure 5, in that 
we can assess the pre, post & their changes of the BMI in (mean ± SD). 
Table.5  Random blood sugar level 
 
Group 
Random blood sugar(RBS)  
P value  
 
Pre treatment Post 
treatment 
Mean 
Decrease 
   Mean ± SD Mean ± SD Mean ± SD 
Monotherapy 
Vildagliptin 
Glibenclamide 
Pioglitazone 
Acarbose 
 
219.4 ± 53.0 
227.4 ± 61.0 
225.4 ± 52.3 
254.1 ± 61.1 
 
170.4 ± 30.6 
177 ± 56.2 
188 ± 42 
236.2 ± 53.2 
 
79.1 ± 42.2 
50.4 ± 49.4 
37.5 ± 45.6 
17.8 ± 61.4 
 
 
 
   0.0001 
Significant 
Combination 
therapy 
Vildagliptin + 
Pioglitazone 
Vildagliptin + 
Metformin 
 
241.5  ± 43.5 
 
281.3 ± 56.5 
 
182.8  ± 54.3 
 
196.4 ± 36.4 
 
58.7  ± 74.4 
 
85  ± 47.2 
  
In that monotherapy group vildagliptin pre-treatment mean value (219.4 ± 53.0) is 
greater than that of other group but its post-treatment day value (170.4 ± 30.6) is 
lesser than that of the pre treatment day value of other group live glibenclamide, 
pioglitazone & acarbose. And also it shows a high mean decrease range (35.0 ± 22.8) 
than other groups. Its mean RBS decreasing rate (79.1 ± 42.2) is twice of pioglitazone 
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(37.5 ± 45.6) group & four and half time more than that of acarbose (17.8 ± 61.4) 
acarbose group. According to sanjay karla 2010, vildagliptin have better effect than 
sulfonyl urea, thiozolidindiones & α-glucosidase inhibitors.  In combination therapy 
group vildagliptin+metformin shows a better mean RBS reduction (85 ± 47.2) than 
that of vildagliptin+pioglitazone group (58.7 ± 74.4).  In both (mono & combination) 
group comparison also vildagliptin +metformin combination (85 ± 47.2) shows better 
decrease than that of vildagliptin alone & vildagliptin +pioglitazone combination. 
And shows a significant P (0.0001) value decrease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Figure .5 Random blood sugar graph
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 Glycosylated haemoglobin level data (HbA1c):-  
                  HbA1c of 207 patients observed and recorded the values of first (pre-
treatment day) visit and third (Post-treatment day). Data is mentioned in the Table-6 
& Figure 6, in that we get  the pre, post & their changes of the HbA1c in (mean ± SD) 
values. In the monotherapy group the vildagliptin group has higher value of pre-
treatment HbA1c (7.81 ± 0.61) than that of other groups, from this we can understand 
vildagliptin is highly preferable in higher range blood glucose level.  
Table.6 Glycosilated heamoglobin data 
  
 
Group 
Glycosilated heamoglobin(HbA1c)  
P value  
 
Pre-
treatment 
Post-
treatment 
Change in 
HbA1c 
Mean ± SD Mean ± SD Mean ± SD 
Monotherapy 
Vildagliptin 
Glibenclamide 
Pioglitazone 
Acarbose 
 
7.81 ± 0.61  
7.37 ± 0.82 
7.45 ± 0.91 
7.67 ± 0.75 
 
7.31 ± 0.62 
7.07 ± 0.77 
7.18 ± 0.72 
7.71 ± 0.67 
 
0.5 ± 0.35 
0.29 ± 0.6 
0.27 ± 0.47 
-0.04 ± 0.28 
 
 
 
 
 0.0001 
Significant Combination therapy 
Vildagliptin + 
Pioglitazone 
Vildagliptin + 
Metformin 
 
                         
7.8 ± 0.53 
 
8.08 ± 0.83 
 
                   
7.13 ± 0.74 
 
7.35 ± 0.64  
 
                       
0.67 ± 0.66 
 
0.73 ± 0.37 
 
And vildagliptin alone group showing a large range of mean ± SD decrease (0.5 ± 
0.35). In acarbose group post-treatment day (7.71 ± 0.67) value is greater than that of 
pre-treatment day (7.67 ± 0.75) value, it shows negative mean decrease (-0.04 ± 0.28) 
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that means it have no effect on blood glucose level.  Ahre´n et al., 2010 conducted 
study also shows a better control of vildagliptin monotherapy on HbA1c. 
  In combination therapy vildagliptin- metformin combination shows greater 
degree of mean decrease (0.73 ± 0.37) than that of vildagliptin+pioglitazone (0.67 ± 
0.66) group. In total group comparison vildagliptin- metformin then 
vildagliptin+pioglitazone are beneficial than that of vildagliptin alone. Ahrén 2008, 
his 52 week study also shows a reducion HbA1c levels by 0.65%–1.1% (baseline 
HbA1c 7.2–8.7%) mean decrease of P (0.0001) value is significant. 
 
 
 
 
 
 
 
 
 
    
          Figure. 6 Glycosylated haemoglobin level 
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Serum Low density lipoprotein level (LDL) data:-  
LDL of two hundred and seven (207) patients observed and recorded the 
values of first (initial therapy) visit and third (final therapy) visit. Data is mentioned in 
the Table-7 & Figure 7, in that we get the initial, final & their changes of the LDL in 
(mean ± SD) values. As we know the anti-diabetics doesn’t have a major role on the 
lipid profiles but also the show some effects. In monotherapy group Glibenclamide 
&Pioglitazone shows a mild mean decrease of LDL (1.4 ± 8.7) & (1.3 ± 5.9) as 
respectively, But in case of vildagliptin & acarbose shows a mild negative decrease 
(increase) of LDL (-1.2 ± 9.4) & (-1.3 ± 4.7) as respectively.  
Table.7 Lipid profile –serum low density lipoprotein 
 
 
      Group 
 Low density lipoprotein(LDL)  
 
   P value  
 
Initial 
therapy 
Final therapy Change in 
LDL 
Mean ± SD  Mean ± SD   Mean ± SD 
Monotherapy 
Vildagliptin 
Glibenclamide 
Pioglitazone 
Acarbose 
 
115.6 ± 11.3 
108 ± 17.0 
113.3 ± 17.1 
113.1 ± 11.8 
 
116.8 ± 11.4 
106.6 ± 15.2 
112.0 ± 16.1 
114.4 ± 10.1 
 
-1.2 ± 9.4 
1.4 ± 8.7  
1.3 ± 5.9 
-1.3 ± 4.7 
 
 
 
0.0985 
Not 
Significant Combination 
therapy 
Vildagliptin + 
Pioglitazone 
Vildagliptin + 
Metformin 
 
                       
123.0 ± 13.9  
 
120.4 ± 18.2 
 
                         
121.7 ± 13.4 
 
115.9 ± 12.3 
 
                         
1.3 ± 5.3 
 
4.5 ± 9.0 
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        Study of Yosefy et al., 2004 on thiazonidinediones (pioglitazone) shows improve 
low density lipoprotein (LDL) particle size by converting the small, dense particles 
into larger, less atherogenic ones 
In combination therapy vildagliptin+metformin combination shows higher ran- ge 
of mean LDL (4.5 ± 9.0) decrease than that of vildagliptin+pioglitazone (1.3 ± 5.3) 
combination therapy group. M.G. Wulffele et al., 2004, Study shows LDL lowering 
effect of metformin. In total group comparison Vildagliptin- metformin combination 
(4.5 ± 9.0) shows better mean LDL decrease than that of  other combination and 
mono therapy groups, the mean LDL decrease P (0.0985) value of  6 sub classes are 
not significant.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
       Figure . 7 Low density lipoprotein level data
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Very low density lipoprotein (VLDL):-  
VLDL of two hundred and seven (207) patients observed and recorded the values 
of first (pre-treatment) visit and third (Post-treatment) visit. Data is mentioned in the 
Table-8 & Figure 8, in that we get the pre, post & their changes of the VLDL in 
(mean ± SD) values. As we know the anti-diabetics doesn’t have a major role on the 
lipid profiles, especially VLDL but also the show some effects as shown in below. 
Table 8- Very low density lipoprotein level data 
 
 
Group 
Very low density lipoprotein(VLDL)  
P value  
 
Pre-treatment Post-treatment Mean 
change 
  Mean ± SD   Mean ± SD Mean ± SD 
Monotherapy 
Vildagliptin 
Glibenclamide 
Pioglitazone 
Acarbose 
 
31.0 ± 5.1 
28.2 ± 6.2 
32.3 ± 5.1 
34.2 ± 5.3 
 
32.5 ± 4.6 
29.8 ± 4.7 
30.9 ± 5.2 
33.8 ± 6.0 
 
-1.5 ± 3.8 
-1.6 ± 4.0 
1.4 ± 3.3 
0.3 ± 3.9 
 
 
 
 
0.0009 
Significant Combination 
therapy 
Vildagliptin + 
Pioglitazone 
Vildagliptin + 
Metformin 
 
              
34.9 ± 5.0 
 
34.5 ± 10.1 
 
              
34.9 ± 3.6 
 
33.4 ± 8.3 
 
            
-0.09 ± 3.2 
 
1.1 ± 3.2 
 
 In monotherapy group pioglitazone (1.4 ± 3.3) & acarbose (0.3 ± 3.9) shows 
(mean ± SD) decrease of VLDL, but in case of vildagliptin & glibenclamide shows 
negative decrease of  (mean ± SD)  of  VLDL (-1.5 ± 3.8) & ( -1.6 ± 4.0) as 
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respectively. Schernthaner et al., 2004, conducted study on effect of pioglitazone on 
VLDL also shows the slight VLDL lowering effect.   
                         In combination therapy group vildagliptin+metformin group shows 
mean decrease VLDL (1.1 ± 3.2), M.G. Wulffele´ et al., 2004, conducted a study on 
metformin also shows reduced triglycerides (is proportional to VLDL) by 0.19 mmol 
L)-1, but in case of Vildagliptin+pioglitazone group shows an negative range of 
decrease of mean VLDL (-0.09 ± 3.2). The P value of mean ± SD value is significant 
(0.0009) for all 6 groups 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
          
 
       Figure.8 Very low density lipoprotein level 
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 Serum high density lipoprotein level (HDL):-  
HDL of two hundred and seven (207) patients observed and recorded the values 
of first (pre-treatment) visit and third (Post-treatment) visit. Data is mentioned in the 
Table-9 & Figure 9, in that we get the pre, post & their changes of the HDL in (mean 
± SD) values. As we know HDL is the good cholesterol, >40 mmol/l is considered as 
normal, because it is essential for some of body activities and production. In 
monotherapy group pioglitazone from the pre-treatment (42.6 ± 5.1) value post-
treatment (44.6 ± 5.2) values shows a positive (mean ± SD) increase of HDL (2.0 ± 
2.8). 
Table.9 Serum high density lipoprotein chart 
 
 
Group 
 High density lipoprotein(HDL)  
 
P value  
 
Pre-
treatment 
Post-
treatment 
Mean 
increase 
  Mean ± SD  Mean ± SD  Mean ± SD 
Monotherapy 
Vildagliptin 
Glibenclamide 
Pioglitazone 
Acarbose 
 
44.1 ± 5.7 
42.6 ± 4.3 
42.6 ± 5.1 
43.4 ± 3.5 
 
40.1 ± 4.9 
42 ± 3.1 
44.6 ± 5.2 
42.7 ± 2.3 
 
-4.0 ± 4.4 
-0.7 ± 3.9 
2.0 ± 2.8 
-0.7 ± 3.2 
 
 
 
0.0001 
Significant 
Combination 
therapy 
Vildagliptin + 
Pioglitazone 
Vildagliptin + 
Metformin 
 
            
43.9 ± 4.4 
 
45.0 ± 5.3 
 
            
42.4 ± 3.1 
 
43.7 ± 4.4 
 
            
-1.5 ± 3.8 
 
-1.3 ± 3.5 
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 Study of Naoumova et al.,2007,conducted a study of Pioglitazone shows a significant 
HDL improvement effect. .But in case of other groups like vildagliptin (-4.0 ± 4.4), 
glibenclamide (-0.7 ± 3.9) & acarbose (-0.7 ± 3.2) shows negative increase and it is 
not beneficial.In case of combination therapy group both combination of vildagliptin 
are showing HDL lowering effect, in vildagliptin+metfomin group (-1.3 ± 3.5) is 
better than that of vildagliptin+pioglitazone (-1.5 ± 3.8) group in the HDL lowering 
effect. In both group comparisons vildagliptin+metfomin is better than 
vildagliptin+pioglitazone & vildagliptin Monotherapy. The P values of mean ± SD 
increase value (0.0001) of all six groups are significant. 
 
 
 
 
 
 
 
 
 
    Figure 11- Mean High density lipoprotein level. 
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Serum Total cholesterol level data (TC):-  
Total cholesterol of two hundred and seven (207) patients observed and recorded 
the values of first (Initial treatment) visit and third (Final treatment) visit. Data is 
mentioned in the Table-10 & Figure 10, in that we get the pre, post & their changes of 
the Total cholesterol in (mean ± SD) values. Most of the dieticians recommend to 
check the total cholesterol at least 6 month intervals, because of its high level total 
cholesterol leads cardiac risk. >200 mg/dl total cholesterol is considered as hyper 
cholesterolemia. 
Table .10 Total cholesterol chart 
 
                   
Group 
 Total cholesterol(TC)  
P value  
 
Initial 
treatment 
Final 
treatment 
Change in 
TC 
Mean ± SD Mean ± SD Mean ± SD 
Monotherapy 
Vildagliptin 
Glibenclamide 
Pioglitazone 
Acarbose 
 
190.6 ± 15.6 
178.0 ± 19.6 
188 ± 20.0 
196.5 ± 21.7 
 
189.2 ± 15.9 
178.5 ± 18.4 
187.4 ± 18.5 
190.9 ± 12.7
 
 1.4 ± 11.5 
-0.4 ± 9.7 
0.6 ± 6.3 
5.5 ± 12.8 
     
    
 
     
0.0216 
SignificantCombination 
therapy 
Vildagliptin 
+Pioglitazone 
Vildagliptin + 
Metformin 
 
               
203.9 ± 22.4 
 
201.6 ± 29.7 
 
           
198 ± 16.2 
 
190.3 ± 25.3
 
            
5.9 ± 13.8 
 
11.9 ± 22.9 
 
         In monotherapy group vildagliptin (-1.4 ± 11.5) & glibenclamide (-0.4 ± 9.7) 
shows a small (mean ± SD) negative decrease of total cholesterol, Pioglitazone (0.6 ± 
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6.3) and acarbose (5.5 ± 12.8) shows a positive decrease of total cholesterol. Study of 
Naoumova et al., 2007, of pioglitazone shows the lowering of total cholesterol and 
total cholesterol HDL cholesterol ratio decrease. In combination therapy group 
vildagliptin+metformin (11.9 ± 22.9) shows greater decrease (mean ± SD) than that of 
vildagliptin+pioglitazone (5.9 ± 13.8) combination. M.G. Wulffele´ et al., 2004, 
conducted a study on metformin also shows reduced total cholesterol. The P value of 
mean decrease rates (0.0216) is significant.                               
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
     Figure 10- Total cholesterol level data. 
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Hepatic safety profile-(LFTs or LFs), are groups of clinical biochemistry 
laboratory blood assays designed to give information about the state of a patient's 
liver. The parameters measured include PT/INR, a PTT, albumin, billirubin (direct 
and indirect) and others. According to some, liver transaminases (AST/ALT 
(SGOT/SGPT) are not liver function tests, but are biomarkers of liver injury in a 
patient with some degree of intact liver function. Most liver diseases cause only mild 
symptoms initially, but it is vital that these diseases be detected early. Hepatic (liver) 
involvement in some diseases can be of crucial importance. This testing is performed 
by a medical technologist on a patient's serum or plasma sample obtained by 
phlebotomy. Several biochemical tests are useful in the evaluation and management 
of patients with hepatic dysfunction. These tests can be used to (1) detect the presence 
of liver disease, (2) distinguish among different types of liver disorders, (3) gauge the 
extent of known liver damage, and (4) follow the response to treatment. Some or all 
of these measurements are also carried out (usually about twice a year for routine 
cases) on those individuals taking certain medications. 
Alanine transaminase (ALT-7-56 IU/L) - also called serum glutamic 
pyruvate transaminase (SGPT) is an enzyme present in hepatocytes (liver cells). 
When a cell is damaged, it leaks this enzyme into the blood, where it is measured. 
Aspartate transaminase (AST 5-40 IU/L)- also called serum glutamic oxaloacetic 
transaminase (SGOT) is similar to ALT in that it is another enzyme associated with 
liver parenchymal cells. It is raised in acute liver damage, but is also present in red 
blood cells and cardiac and skeletal muscle and is therefore not specific to the liver. 
The ratio of AST to ALT is sometimes useful in differentiating between causes of 
liver damage.   
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Hepatic safety profile - Alanine transaminase (ALT):- 
ALT of two hundred and seven (207) patients observed and recorded the values 
of first (pre-treatment day) visit and third (Post-treatment day). Data are recorded in 
the Table-11 & Figure 11, in that we get the pre, post & their changes of the ALT in 
(mean ± SD) values. Most of the diabeticians recommend checking the ALT at least 
one year intervals, its small range variation not considered as any hepatic disorder, it’s 
twice/trice will indicate hepatic toxicity or disorder.  
Table 11-Alanine transaminase level data 
 
 
Group 
Alanine  transaminase(ALT)  
 
P value  
 
Pre-
treatment 
Post-
treatment 
Mean 
change 
Mean ± SD Mean ± SD Mean ± SD 
Monotherapy 
Vildagliptin 
Glibenclamide 
Pioglitazone 
Acarbose 
 
26.5 ± 8.0 
27.5 ± 6.6 
28.8 ± 9.4 
25.8 ± 5.6 
 
28.5 ± 7.7 
27.7 ± 6.7 
29.3 ± 9.6 
25.8 ± 5.3 
 
1.9 ± 2.1 
0.2 ± 1.4 
0.5 ± 1.0 
0 ± 1.0 
 
 
 
  0.0001 
Significant 
Combination 
therapy 
Vildagliptin + 
Pioglitazone 
Vildagliptin + 
Metformin 
 
             
26.4 ± 6.5 
 
26.2 ± 6.7 
 
             
27.9 ± 5.9 
 
26.2 ± 6.8 
 
            
1.5 ± 2.1 
 
0.04 ± 0.7 
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In the monotherapy group vildagliptin (1.9 ± 2.1) shows more increase than 
that of other groups, acarbose (0 ± 1.0) shows least increase of ALT. Glibenclamide 
(0.2 ± 1.4) & pioglitazone (0.5 ± 1.0) also shows a slight increase of AST, Tolman K 
G et al., 2009, conducted a 12 week study of pioglitazone & glibenclamide shows the 
slight increase of ALT.  In combination therapy group vildagliptin+pioglitazone (1.5 
± 2.1) shows more increase than that of vildagliptin- metformin (0.04 ± 0.7), that 
means vildagliptin+metformin is beneficial than that of vildagliptin+pioglitazone & 
vildagliptin monotherapy. The P value mean decreases (0.0001) of six groups are 
significant.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
      Figure.11 Alanine transaminase level data 
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Hepatic safety profile – Aspartate transaminase (AST):- 
AST 207 patients observed and recorded the values of first (pre-treatment) 
visit and third (Post-treatment) visit. Data are recorded in the Table-12 & Figure 12, 
in that we get the pre, post & their changes of the AST in (mean ± SD) values. Most 
of the diabeticians recommend to check the AST at least one year intervals, Its value 
or AST-ALT ratio is very helpful to check the hepatic disorder, it’s twice/trice of  the 
upper limit of the normal values considered as hepatic disorders or toxicity.  
Table.12 Aspartate transaminase level data. 
 
 
Group 
Aspartate transaminase(AST)  
P value  
 
Pre-
treatment 
Post-
treatment 
Change in 
AST 
Mean ± SD Mean ± SD Mean ± SD 
Monotherapy 
Vildagliptin 
Glibenclamide 
Pioglitazone 
Acarbose 
 
23.3 ± 6.6 
23.5 ± 5.2 
24.5 ± 8.1 
20.8 ± 3.8 
 
24.2 ± 6.6 
23.7 ± 5.2 
25.0 ± 8.0 
22.1 ± 4.9 
 
0.9 ± 1.7 
0.2 ± 1.4 
0.5 ± 1.3 
1.3 ± 1.5 
 
 
 
    0.0004 
Significant 
Combination 
therapy 
Vildagliptin + 
Pioglitazone 
Vildagliptin + 
Metformin 
 
              
23.5 ± 5.9 
 
23.4 ± 6.6 
 
             
24.7 ± 5.2 
 
23.3 ± 6.3 
 
            
1.2 ± 2.2 
 
-0.1 ± 0.9 
 
In monotherapy group acarbose (1.3 ± 1.5) shows the highest (mean ± SD) rate of 
increase, Study of M Malaguarnera et al., 1999, on acarbose shows the slight increase 
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of AST. Vildagliptin (0.9 ± 1.7) is the second most AST increase in the monotherapy 
group, but these increases are very milder range & they doesn’t mean any hepatic 
damages (liver toxicity). In combination therapy group vildagliptin+pioglitazone (1.2 
±  2.2) shows more increase than that of vildagliptin+ metformin (-0.1 ±  0.9) and 
vildagliptin+ metformin group shows a milder decrease of AST & it is a beneficiary 
effect, that means vildagliptin+metformin is beneficial than that of 
vildagliptin+pioglitazone & vildagliptin monotherapy. The P value mean decrease 
(0.0001) of six groups is significant.   
 
 
          Figure. 12 Aspartate transaminase level data 
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Adverse drug reaction report:- 
Adverse drug reaction of two hundred and seven (207) patients are checked during 
their regular visit, mostly adverse drug reaction report are collected in the third visit. 
Most of the adverse drug reaction reported here are expectable types. Weight gain, 
abdominal pain, constipation, diarrhea, nausea, muscle pain, hypoglycemia, 
hyperglycemia are the most common reported adverse drug reactions.  
Table 13-Adverse drug reaction (ADR) summary and most common ADRs   
 
Adverse 
drug 
Reaction 
No. of incidences in adverse  reaction & its percentage  
Monotherapy                                       Combined therapy 
Vild (34) Gli  
(47) 
Pio  
(39) 
Acrbs 
(13) 
Total 
(133) 
Vil+Pio 
(34) 
Vil+Met 
(40) 
Total 
(74) 
Weight 
gain 
10 29.4 6 12.8 15 38.5 - - 31 23.3 13 38.2 1 2.5 14 18.9 
Abdomina
l Pain 
- - - - 1 2.6 - - 1 0.8 - - 1 2.5 1 1.4 
Constipati
on 
- - 4 8.5 3 7.7 1 7.7 8 6.0 1 2.9 3 7.5 4 5.4 
Diarrhea 1 2.9 2 4.3 - - - - 3 2.3 1 2.9 1 2.5 2 2.7 
Nausea - - 2 4.3 - - - - 2 1.5 1 2.9 - - 1 1.4 
Muscle 
pain 
- - - - 1 2.6 -  1 0.8 - - - - - - 
Hypo 
glycemia 
- - 3 6.4 2 5.1 - - 5 3.8 6 17.6 - - 6 8.1 
Hyper 
glycemia 
- - 2 4.3 1 2.6 5 38.5 8 6.0 1 2.9 - - 1 1.4 
Any one 
complaint 
11 32.4 19 40.4 22 56.4 6 46.2 58 43.6 21 61.8 5 12.5 27 36.5 
 
5 cases had more than one complication. 
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The weight gain 45 (21.73%) is the most seeing adverse drug reaction, muscle pain 
1 (0.48%) is the least reported one. From the total two hundred and seven (207) 
patients 85 (41.06%) patients shows any one of the adverse drug reaction, and 5 
(2.41) showing more than one adverse drug reaction. 
                  In monotherapy group vildagliptin shows lowest 11 (32.4%) percentage of 
the adverse drug reaction, study of Schweizer et al., 2011, also shows the drug-related 
AEs Were seen with a lower frequency in vildagliptin-treated patients (15.7%) and 
the pioglitazone shows the highest 22(56.4%) percentage of adverse drug reaction. In 
the combination therapy group Vildagliptin+metformin shows least 5(12.5%) adverse 
drug reaction than that of Vildagliptin+pioglitazone group.  
 
 
 
 
 
 
 
 
 
 
 
        
 
   Figure.13 Adverse drug reaction (ADR) summary and most common ADRs   
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DISCUSSION 
All together two hundred and seven (207) patients were enrolled in to the 
study over a period of 10 months, In that males 133 (64.25%) and   females 74 
(35.74%). The total patients are classified in to two groups based on the number of 
drug consumption (Monotherapy & Combination therapy) in monotherapy group 
males 86(64.7%) & females 47(35.3%) are there out of 133,in combination therapy 
consist of 74 patients in that 47(63.3%) males & 27 females(36.5%). This study 
shows the prevalence of diabetics in male than that of female. 
Based on age wise distribution patients are divided in to five age groups. They 
are 35-45 year, 46-55 year, 56-65 years, 66-75 years, and 76-85 years. In that more 
patients 67 (32.36%) are in age group of 46-55 years & 56-65 years in each group. 
Usually 50-70 years are more prominent age group in type 2 diabetes, because these 
age group food consumption and food utilization ratio are entirely different. It makes 
these age group is more prominent than other groups. 
Among the study population 176 (85.02%) have family history of diabetes 
mellitus & 31(14.97%) doesn’t with family history. Diabetes is highly depend on 
family history & hereditary. 
Body mass index denote the body weight-height ratio, the optimum BMI is 
considered as 18-22 kg/m2. The drug which has the BMI lowering effect is highly 
beneficial in obese & over weight patients; in our monotherapy group vildagliptin 
group only shows positive weight (0.24 ± 0.52) decrease, other groups doesn’t shows 
any weight lowering effect. In combination therapy Vildagliptin + Metformin group 
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(0.41 ± 0.53) only shows greater decline of body weight, but not by Vildagliptin+ 
Pioglitazone. 
A good anti-diabetic drug shows considerable blood sugar lowering effect 
without causing hypoglycemia. On the basis of fasting blood sugar (FBS) In our 
monotherapy all groups except acarbose shows considerable lowering of blood sugar, 
compare to other group vildagliptin shows higher decrease (35.0 ± 22.8) range. In 
combination therapy both groups shows fasting blood sugar lowering effect, 
vildagliptin + metformin shows more (36.5 ± 27.6) effect than vildagliptin + 
pioglitazone (31.8 ± 47.4). 
Random blood sugar (RBS) lowering also one of the identical parameter to 
check the efficacy of an anti- diabetic drug. In monotherapy group vildagliptin shows 
higher degree (79.1 ± 42.2) of random blood sugar (RBS) lowering effect than that of 
other group, in combination therapy both are highly effective, but also vildagliptin + 
metformin shows more (85 ± 47.2) effect than vildagliptin + pioglitazone (58.7  ± 
74.4). 
Glycosylated haemoglobin (HbA1c) is the most relevant & prominent 
parameter to assess the efficacy and effectiveness of an anti diabetic drug. But it not 
widely used because of its cost; it is very useful to detect the blood sugar level of a 
period time. In our monotherapy group all group except acarbose shows significant 
decrease of HbA1c, in that vildagliptin (0.5 ± 0.35) shows the greater decreasing 
effect. In combination therapy vildagliptin + metformin (0.73 ± 0.37) shows greater 
effect than that of vildagliptin + pioglitazone (0.67 ± 0.66). 
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As we know the anti-diabetics doesn’t have a major role on the lipid profiles 
but also the show some effects. In monotherapy group Glibenclamide &Pioglitazone 
shows a mild mean decrease of LDL (1.4 ± 8.7) & (1.3 ± 5.9) as respectively, But in 
case of vildagliptin & acarbose shows a mild negative decrease (increase) of LDL (-
1.2 ± 9.4) & (-1.3 ± 4.7) as respectively. In combination therapy vildagliptin + 
metformin combination shows higher range of mean LDL (4.5 ± 9.0) decrease than 
that of vildagliptin + pioglitazone (1.3 ± 5.3) combination therapy group. 
            The VLDL change of our study shows as follows in monotherapy group; 
pioglitazone (1.4 ± 3.3) & acarbose (0.3 ± 3.9) only shows (mean ± SD) decrease of 
VLDL, but in case of vildagliptin & glibenclamide shows negative decrease of  (mean 
± SD)  of  VLDL (-1.5 ± 3.8) & ( -1.6 ± 4.0) as respectively. In combination therapy 
group vildagliptin+metformin group shows mean decrease VLDL (1.1 ± 3.2). 
 High density lipoprotein is considered as good cholesterol, it is one of the 
energy donor of our body, its increasing effect is considered as one of the beneficial 
effect. In our monotherapy study pioglitazone shows a positive (mean ± SD) increase 
of HDL (2.0 ± 2.8). but in combination therapy group both combination of 
vildagliptin are showing HDL lowering effect. 
 Increased total cholesterol level (>200 mg/dl) leads to high cardiac risk, its 
lowering effect is highly beneficial. In our monotherapy group only vildagliptin (1.4 ± 
11.5) shows significant TC decrease. In combination therapy group vildagliptin + 
metformin & vildagliptin + pioglitazone shows TC lowering effect as   (11.9 ± 22.9) 
& (5.9 ± 13.8) respectively. 
Chapter 7 Discussion 
 
 
 
Department of Pharmacy Practice J.K.K.M.M.R.F College of Pharmacy 
 
70
 Hepatic safety profile is one of the major safety profiles, because the entire 
drug metabolism is takes place at liver only. For these purpose Aspartate transaminase 
(AST) & Alanine transaminase (ALT) are done at specific intervals. But its twice or 
trice amount of the normal value is considered as hepatic toxicity or damage. In our 
monotherapy study all drug groups except acarbose (acarbose shows neutral effect on 
ALT) shows increased value of AST & ALT. 
                   Adverse drug reactions are the unwanted effects of a drug in its 
therapeutic doses. In our study; monotherapy group vildagliptin shows lowest 11 
(32.4%) percentage of the adverse drug reaction. In the combination therapy group 
Vildagliptin+metformin shows least 5(12.5%) adverse drug reaction than that of 
Vildagliptin+pioglitazone group. 
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CONCLUSION 
   
DPP-4 inhibition is efficient in reducing Glycosylated haemoglobin (HbA1c), 
fasting blood sugar (FBS) & random blood sugar (RBS). In the monotherapy Setting, 
DPP-4 has produced a reduction of approximately 0.5±0.35 in HbA1c, 35± 22.8 in 
FBS & 79.1± 42.2 in RBS are shown in different age and sex population & it shows a 
decreasing effect of BMI, serum lipid profile – high density lipoprotein (HDL) & total 
cholesterol (TC). Vildagliptin shows a slight increasing effect of LDL, VLDL. DPP-4 
inhibition is also safe and tolerable is because it shows very slight increase of Hepatic 
safety profile AST (0.9±1.7) & ALT (1.9 ± 2.1), and also it shows less (11) number of 
Adverse drug reaction than that of other group. 
   
In combination therapy setting, Vildagliptin+metformin shows more 
beneficial effect than that of Vildagliptin+pioglitazone in lowering effect of FBS, 
RBS, HbA1c, BMI, Lipid profile LDL, VLDL, TC, Hepatic safety profile ALT, AST 
& least number of Adverse effect.   
          
Therefore, DPP-4 inhibition is a new, efficient and tolerable treatment of type 
2 Diabetes that may improve the disease process. It may be suggested that a primary 
place for DPP-4 inhibition is as a first-line treatment since it is efficient, safe, 
tolerable and orally active. Furthermore, the efficiency of DPP-4 inhibition in 
combination both with metformin and with TZDs suggests that it may be useful as 
combination therapy.  
 
Chapter 8 Conclusion 
 
Department of Pharmacy Practice J.K.K.M.M.R.F College of Pharmacy 
 
72
Encouragingly, the safety and tolerability data from combination studies show 
that addition of a DPP-4 inhibitor to the ongoing monotherapy regimen has similar 
incidences of adverse effects versus monotherapy. Furthermore, there is a low 
incidence of hypoglycemia in the combination regimens. Long-term studies are now 
warranted to show the durability and long-term safety of this approach to treat type 2 
diabetes. 
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FUTURE RECOMMANDATION 
 
• In monitoring of glycemic control is performed by the patients measuring their 
own plasma or blood glucose with meters and by laboratory analysis of HbA1c. 
The potential roles of noninvasive glucose monitoring, genetic testing, and 
measurement of auto antibodies, urine albumin, insulin, proinsulin, C-peptide, 
and other analytes are addressed. 
• Lifestyle influences the development of type 2 diabetes. Obesity tends to run 
in families, and families tend to have similar eating and exercise habits ,so 
recommend to patients to follow healthy diet & regular exercise 
•  Screening Recommendations for Asymptomatic Persons those have above 45 
year age / having BMI ≥ 27 kg/m2  (or) HDL cholesterol level ≤35 mg per dL 
(0.90 mmol per L) and/or triglyceride level ≥ 250 mg per dL (2.83 mmol per 
L)(or) Hypertensive (≥ 140/90 mm Hg) recommend them to test and repeat 
every three year.  
• Prepare diet plan for a diabetic is based on height, weight, age, sex, physical 
activity and nature of diabetes. While planning diet, the dietician has to 
consider complications such as high blood pressure, high cholesterol levels 
• Like diabetes, high blood pressure can damage our blood vessels. High 
cholesterol is a concern, too, since the damage is often worse and more rapid 
when you have diabetes. When these conditions team up, they can lead to a 
heart attack, stroke or other life-threatening conditions. 
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• Schedule yearly and regular kidney function to detect diabetic nephropathy, 
because it is one of the major diabetic complications. 
• Advice to check hepatic functional test to patients those are taking diabetics 
drugs especially vildagliptin. 
• Diabetes may leave you prone to gum infections. Brush your teeth at least 
twice a day, floss your teeth once a day, and schedule dental exams at least 
twice a year. Consult your dentist right away if your gums bleed or look red or 
swollen. 
• Consider a daily aspirin- Aspirin reduces blood’s ability to clot. Taking a daily 
aspirin can reduce your risk of heart attack and stroke. 
• Recommend to control stress, stress will prevent insulin from working 
properly, which only makes matters worse. To take control, set limits. 
Prioritize your tasks. Learn relaxation techniques. Get plenty of sleep.  
• Incidence of hypoglycemia is more with pioglitazone, so recommend the 
patient to take food as soon as possible while taking medicine. 
• Recommend the obese patient to include metformin to their drug to reduce 
weight vildagliptin taking patients those  having impaired LDL,VLDL,HDL, 
recommend  to add metformin. 
• The increased study population need to get more clear data 
• To get the exact ADRs & Safety profile need more time period to study. 
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